VISUPRIME® Eye Drops

Inclusion Criteria: * Adult patients (age ≥ 18) * Naïve and pre-treated patients scheduled for IVI * Diagnosis of one of the following: * ARMD * mCNV * Proliferative diabetic retinopathy * Diabetic macular oedema * Macular oedema secondary to retinal vein occlusion * The subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the local Ethics Committee (EC). Exclusion Criteria: * Use of systemic antibiotics, corticosteroids within 3 months * Use of topical antibiotics and or corticosteroids within 15 days from study enrolment * Use of topical Artificial Tears within 15 days from the enrolment * Use of topical antiseptic agents within 1 month from study enrolments * Presence of topical ocular therapies that cannot be suspended for the entire duration of the study * Ongoing ocular or systemic inflammatory or infectious processes * Known hypersensitivity to the constituents of the study product * Diagnosis of Open-Angle Glaucoma * Uveitis * Acute and Chronic Conjunctival Disease * Any intraocular surgery within 6 months from study enrolment, excluded IVI * Severe and Moderate Dry Eye * Pregnancy or breast-feeding * Participation in other clinical studies * Patients with cognitive impairment and unable to manage home-assigned treatment.